Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGEN
CUSIPN/A
Phone972-3765-8585
Debt
Debt-to-Equity RatioN/A
Current Ratio5.92
Quick Ratio5.92
Price-To-Earnings
Trailing P/E Ratio-4.38
Forward P/E Ratio-7.56
P/E GrowthN/A
Sales & Book Value
Annual Sales$710,000.00
Price / Sales245.61
Cash FlowN/A
Price / CashN/A
Book Value$0.57 per share
Price / Book5.96
Profitability
EPS (Most Recent Fiscal Year)($0.72)
Net Income$-37,060,000.00
Net MarginsN/A
Return on Equity-84.71%
Return on Assets-66.55%
Miscellaneous
Employees101
Outstanding Shares51,290,000
Market Cap$156.44 million
Compugen (NASDAQ:CGEN) Frequently Asked Questions
What is Compugen's stock symbol?
Compugen trades on the NASDAQ under the ticker symbol "CGEN."
How were Compugen's earnings last quarter?
Compugen Ltd. (NASDAQ:CGEN) announced its earnings results on Wednesday, August, 1st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). View Compugen's Earnings History.
When is Compugen's next earnings date?
What price target have analysts set for CGEN?
2 analysts have issued 1-year target prices for Compugen's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Compugen's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 172.7% from the stock's current price. View Analyst Price Targets for Compugen.
What is the consensus analysts' recommendation for Compugen?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen.
Who are some of Compugen's key competitors?
Some companies that are related to Compugen include Fate Therapeutics (FATE), La Jolla Pharmaceutical (LJPC), Mesoblast (MESO), Voyager Therapeutics (VYGR), Vericel (VCEL), Novavax (NVAX), Replimune Group (REPL), Nightstar Therapeutics (NITE), Translate Bio (TBIO), NanoString Technologies (NSTG), Scholar Rock (SRRK), PDL BioPharma (PDLI), Cellular Biomedicine Group (CBMG), Neon Therapeutics (NTGN) and Adverum Biotechnologies (ADVM).
Who are Compugen's key executives?
Compugen's management team includes the folowing people:
- Dr. Anat Cohen-Dayag, Chief Exec. Officer, Pres and Director (Age 51)
- Mr. Ari Krashin, Chief Financial and Operating Officer (Age 45)
- Mr. Kirk A. Christoffersen MBA, Sr. VP of Corp. and Bus. Devel. (Age 49)
- Dr. Zurit Levine Ph.D., VP of Research & Discovery (Age 50)
- Dr. John J. Hunter, VP of Antibody R&D (Age 55)
Has Compugen been receiving favorable news coverage?
Press coverage about CGEN stock has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Compugen earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 47.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Compugen.
Who are Compugen's major shareholders?
Compugen's stock is owned by a number of of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.48%), Taylor Frigon Capital Management LLC (1.30%), Renaissance Technologies LLC (0.48%), Benjamin F. Edwards & Company Inc. (0.33%) and Commonwealth Equity Services LLC (0.06%).
Which institutional investors are selling Compugen stock?
CGEN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
Which institutional investors are buying Compugen stock?
CGEN stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Taylor Frigon Capital Management LLC, Benjamin F. Edwards & Company Inc. and Commonwealth Equity Services LLC.
How do I buy shares of Compugen?
Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Compugen's stock price today?
One share of CGEN stock can currently be purchased for approximately $3.30.
How big of a company is Compugen?
Compugen has a market capitalization of $156.44 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-37,060,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 101 workers across the globe.
How can I contact Compugen?
Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]
MarketBeat Community Rating for Compugen (NASDAQ CGEN)
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
